129 related articles for article (PubMed ID: 26838018)
1. The Cobas® EGFR Mutation Test v2 assay.
Brown P
Future Oncol; 2016 Feb; 12(4):451-2. PubMed ID: 26838018
[TBL] [Abstract][Full Text] [Related]
2. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
Malapelle U; Sirera R; Jantus-Lewintre E; Reclusa P; Calabuig-Fariñas S; Blasco A; Pisapia P; Rolfo C; Camps C
Expert Rev Mol Diagn; 2017 Mar; 17(3):209-215. PubMed ID: 28129709
[TBL] [Abstract][Full Text] [Related]
3. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Sequist LV; Bell DW; Lynch TJ; Haber DA
J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
[TBL] [Abstract][Full Text] [Related]
4. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer.
Kimura H; Ohira T; Uchida O; Matsubayashi J; Shimizu S; Nagao T; Ikeda N; Nishio K
Lung Cancer; 2014 Mar; 83(3):329-33. PubMed ID: 24439568
[TBL] [Abstract][Full Text] [Related]
5. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
6. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
[No Abstract] [Full Text] [Related]
7. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
9. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
11. INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.
Govindan R
J Clin Oncol; 2010 Feb; 28(5):713-5. PubMed ID: 20038722
[No Abstract] [Full Text] [Related]
12. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.
Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Huang KT; Chen HC; Lin MC
Lung Cancer; 2016 Mar; 93():47-54. PubMed ID: 26898614
[TBL] [Abstract][Full Text] [Related]
13. Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?
Chiu CH; Chou TY; Chiang CL; Tsai CM
Cancer Chemother Pharmacol; 2014 Oct; 74(4):661-5. PubMed ID: 25053390
[TBL] [Abstract][Full Text] [Related]
14. Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
Kuiper JL; Ronden MI; Becker A; Heideman DA; van Hengel P; Ylstra B; Thunnissen E; Smit EF
J Clin Pathol; 2015 Apr; 68(4):320-1. PubMed ID: 25661795
[No Abstract] [Full Text] [Related]
15. [I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].
Urata Y; Satouchi M
Gan To Kagaku Ryoho; 2015 Aug; 42(8):931-4. PubMed ID: 26353389
[No Abstract] [Full Text] [Related]
16. Gefitinib Approved for EGFR-Mutated NSCLC.
Cancer Discov; 2015 Sep; 5(9):896. PubMed ID: 26238462
[No Abstract] [Full Text] [Related]
17. Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.
Gauthier H; Douchet G; Lehmann-Che J; Meignin V; Raynaud C; Sabatier P; de Cremoux H; Poirot B; Culine S; Pouessel D; de Cremoux P
J Thorac Oncol; 2014 Oct; 9(10):e78-9. PubMed ID: 25521408
[No Abstract] [Full Text] [Related]
18. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatment for advanced lung cancer with EGFR mutation.
Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
